A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.
Cancer|Melanoma
DRUG: BMS-986253|BIOLOGICAL: Nivolumab|BIOLOGICAL: Ipilimumab|OTHER: Placebo
Incidence of adverse events (AE), Part 1, Approximately 5 years|Incidence of serious adverse events (SAE), Part 1, Approximately 5 years|Incidence of AEs meeting protocol-defined dose limiting toxicities (DLT) criteria, Part 1, Approximately 5 years|Incidence of AEs leading to discontinuation, Part 1, Approximately 5 years|Incidence of deaths, Part 1, Approximately 5 years|Incidence of clinically significant changes in clinical laboratory results: Hematology tests, Part 1, Approximately 5 years|Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests, Part 1, Approximately 5 years|Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests, Part 1, Approximately 5 years|ORR based on Blinded independent central review (BICR) assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in all randomized patients, Part 2, Approximately 5 years
Objective response rate (ORR) based on Blinded independent central review (BICR) assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator, Part 1, Approximately 5 years|Duration of response (DOR) per response evaluation criteria in solid tumors (RECIST) v1.1 per investigator, Part 1, Approximately 5 years|Incidence of anti-drug antibody (ADA) to BMS-986253, Part 1, Approximately 5 years|Serum biomarker concentration, Part 1, Approximately 5 years|Maximum observed serum concentration (Cmax), Part 1, Approximately 5 years|Time of maximum observed serum concentration (Tmax), Part 1, Approximately 5 years|Area under the serum concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)], Part 1, Approximately 5 years|Area under the serum concentration-time curve in 1 dosing interval [AUC(TAU)], Part 1, Approximately 5 years|Observed serum concentration at the end of a dosing interval (CTAU), Part 1, Approximately 5 years|Trough observed serum concentration at the end of the dosing interval (CTROUGH), Part 1, Approximately 5 years|Progression-free survival (PFS) hazard ratio based on Blinded independent central review (BICR) assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, Part 2, participants with advanced melanoma, using RECIST v1.1 (regardless of baseline serum IL-8 levels), Approximately 5 years|Incidence of AEs, Part 2, Approximately 5 years|Incidence of SAEs, Part 2, Approximately 5 years|Incidence of AEs leading to discontinuation, Part 2, Approximately 5 years|Incidence of death, Part 2, Approximately 5 years|Incidence of clinically significant changes in clinical laboratory results: Hematology tests, Part 2, Approximately 5 years|Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests, Part 2, Approximately 5 years|Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests, Part 2, Approximately 5 years
The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.